Sat Kartar Shopping Limited, now operating as Sat Kartar Life Limited (formerly known as Sat Kartar Shopping Limited), has informed the stock exchange of receiving a no-objection letter from the National Stock Exchange of India Limited (NSE) for the reclassification of SK Sarthi Private Limited from the 'Promoter Group' category to the 'Public' category shareholder of the company. The intimation was made on May 06, 2026, in compliance with Regulation 31A of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

NSE No-Objection: Key Details

The company had submitted an application to NSE on January 28, 2026, seeking the reclassification. NSE subsequently issued its no-objection letter bearing reference number NSE/LIST/COMP/SATKARTAR/554/2026-27, dated May 06, 2026. The key details of the reclassification are summarised below:

Shareholder Approval Not Required

The company has clarified that shareholder approval is not required for this reclassification. As per Regulation 31A of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, shareholder approval is not mandated when the promoter group entity seeking reclassification holds less than 1% of the paid-up share capital of the company. SK Sarthi Private Limited falls within this threshold.

Compliance and Disclosure

The company has been directed by NSE to ensure compliance with subsequent relevant disclosures of material events related to this reclassification, in accordance with the applicable provisions of Regulation 31A of SEBI LODR Regulations, 2015. The information has also been uploaded on the company's official website at www.satkartar.in . The intimation was signed by Sonal Seth, Company Secretary and Compliance Officer (Membership No. A13949), from the company's registered office at 603, 6th Floor, Mercantile House, KG Marg, New Delhi - 110001.

Sat Kartar Life Ltd has announced its audited financial results for the year ended March 31, 2026, following a Board meeting held on May 5, 2026. The Ayurvedic Healthcare and Wellness company reported robust consolidated performance, with revenue rising 23.19% year-over-year to ₹200.70 Cr from ₹162.92 Cr in FY25. Profit After Tax (PAT) for the full year surged 74.31% to ₹17.10 Cr, compared to ₹9.81 Cr in the previous year. The company filed an Investor Presentation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 on May 6, 2026, providing a comprehensive view of its financial and strategic progress.

Financial Performance

The company's profitability metrics showed substantial improvement during the fiscal year. EBITDA for FY26 rose 73.51% to ₹24.69 Cr, with margins expanding by 357 basis points to 12.30%. For the second half of FY26 (H2FY26), revenue stood at ₹110.62 Cr, an increase of 26.96% from ₹87.13 Cr in the corresponding period of the previous year, while EBITDA margin for H2FY26 stood at 13.44%, an improvement of 357 basis points. PAT for H2FY26 grew 63.61% to ₹9.80 Cr, with a PAT margin of 8.86% (up 198 basis points). For the full year, PAT margin expanded 252 basis points to 8.52%. Earnings Per Share (EPS) for the year increased 47.35% to 10.86.

The detailed consolidated Profit & Loss statement is presented below:

Balance Sheet Highlights

The investor presentation also disclosed the company's consolidated balance sheet position across three fiscal years. Total assets and liabilities stood at ₹84.85 Cr as of March 2026, compared to ₹65 Cr in March 2025 and ₹22 Cr in March 2024, reflecting significant balance sheet expansion. Fixed assets grew to ₹11.21 Cr from ₹7 Cr in the prior year, while borrowings declined to ₹2.41 Cr from ₹6 Cr, indicating improved financial leverage.

Strategic Developments

During the period, Sat Kartar Life initiated operations of its first Sat Kartar Sanjeevan Ayurveda Hospital in Delhi, a 30-bed facility offering authentic Ayurvedic treatments. The company successfully raised ₹48.58 Cr through a preferential issue at ₹172 per equity share/warrant, led by institutional investors and HNIs, to support healthcare expansion. A 3-year strategic MoU was signed in April 2026 with Jeena Sikho Lifecare Ltd to build a scalable Ayurveda healthcare ecosystem, leveraging joint capabilities in distribution, product development, and patient outreach. Additionally, the company is acquiring an additional 24% stake in Plantomed Neutraceuticals for ₹1.21 Cr, making it a 100% wholly owned subsidiary, with Plantomed targeting revenues of ₹40–60 Cr by FY28. Four new call centres were commissioned across Tamil Nadu, Karnataka, Andhra Pradesh, and NCR to improve reach and support product expansion. The company's AI initiatives are delivering a 15–20% conversion uplift and lower cost-per-lead, supported by a 30M+ database.

Future Outlook

Management expressed confidence in achieving a medium-term revenue target of ₹500 Crore by FY28, driven by a dual-engine model combining its products business and healthcare platform. Plans include expanding hospital capacity from 30 to 300 beds by FY27, with hospitals expected to contribute ₹100+ Cr in revenue by FY28. The company also intends to expand into global markets, including the US, through high-margin nutraceutical segments under its Plantomed subsidiary, and scale premium wellness offerings under its Vedabay brand.